The alkyl glycerol ether rac-1-O-dodecylglycerol inhibited the growth of members of two genera of yeasts, Candida and Cryptococcus, and was strongly synergistic with amphotericin B. At one-half its MIC, dodecylglycerol decreased the MIC of amphotericin B by as much as 80-fold. This high degree of synergism between dodecylglycerol and amphotericin B was demonstrated against a number of species ofyeasts including Candida albicans, Candida tropicalis, Candida parapsilosis, Cryptococcus neoformans, Cryptococcus albidus, and Cryptococcus laurentii. All fractional inhibitory concentrations (for all strains and species) were calculated to be less than 1, and most were less than 0.6, again demonstrating strong synergism. Other alkyl glycerol ethers with alkyl chain lengths ranging from 8 to 18 carbon atoms were also found to be synergistic with amphotericin B against C. neoformans and C. albicans. Electron microscopy experiments showed that C. neoformans grown in the presence of dodecylglycerol had severely abnormal, deformed capsules. Although the mechanism of action of dodecylglycerol is not known, dodecylglycerol was not simply acting as a detergent. The natural detergent sodium deoxycholate could not substitute for dodecylglycerol. At comparable and higher concentrations, sodium deoxycholate had no fungicidal effect on its own, nor did it potentiate the activity of amphotericin B.
Dodecylglycerol did not interact synergistically with the water-soluble antifungal agent fluconazole. The lipid-soluble hydrophobic properties of amphotericin B appear to be important for this synergistic elfect, in that alkyl glycerol ethers could promote synergism with amphotericin B by potentially increasing the interaction between membrane-bound ergosterol and amphotericin B.
The human immunodeficiency virus epidemic has brought about a dramatic increase in the incidence of opportunistic infections, many of which are caused by fungi. There are relatively few effective antifungal agents that can be used to treat these opportunistic infections, largely because of either the toxicity of the agent or the development of resistance by the infecting organism (2) . One of the most common antifungal agents used to treat life-threatening fungal infections is amphotericin B (AmB), a polyene antibiotic isolated from Streptomyces nodosus (2) . The primary target of AmB is ergosterol, the main sterol in fungal cell membranes (2) . AmB binds to ergosterol, increasing cell membrane permeability, permitting leakage of intracellular constituents, and ultimately, producing cell lysis and death (11) . Although the major affinity of AmB is for ergosterol, the drug also has an affinity for cholesterol, the sterol found at the highest concentrations in the membranes of mammalian cells (2) . Because of this affinity, AmB can be toxic to cholesterol-containing cells and, in many cases, cannot be given in sufficiently high doses to kill all of the fungi. AIDS patients who survive the fungal infection must receive lifelong preventive therapy such as intravenous treatment with AmB once or twice weekly and/or with fluconazole daily (2, 3) .
rac-1-O-Dodecylglycerol (DDG), an alkyl ether lipid ( Fig.  1) , is a potent gram-positive antibacterial agent (5, [16] [17] [18] [19] bacterial cell walls (16) (17) (18) . DDG does not simply act as a detergent and physically dissolve components of the cell wall. Because of DDG's bactericidal activity, the antifungal activity of DDG was tested against species of Candida and Cryptococcus, the major genera causing fungal infections in AIDS patients. DDG was found not only to inhibit the growth of both genera but also to act in a dramatically synergistic fashion with AmB.
MATERIALS AND METHODS
Fungi. All fungi tested were originally isolated from clinical material. From ether. Chimyl alcohol (1-O-hexadecyl-sn-glycerol) was purchased from Sigma. Selachyl alcohol (1-O-9'-cis-octadecenylsn-glycerol) was synthesized by the technique of Baumann and Mangold (1) and was purchased from Deva Biotech, Inc., Hatboro, Pa. The purity was verified by ascending thin-layer chromatography on silica gel G developed with either chloroform-methanol-ammonium hydroxide-water (60:25:1.5:3; volV 20 25 vol) or petroleum ether-ethyl ether (60:40; volUvol). The compounds were made visible by exposure to iodine vapor. Only one spot was visible for each compound (100 ,g was applied). The melting points were also determined and were very close to published values. The trimethylsilyl derivatives of decyl-, dodecyl-and tetradecylglycerol ethers were applied separately to a Packard gas chromatograph by using a column of 3% SE-30 on Chromosorb W (HW) and a temperature of 215°C.
Single peaks with retention times of 1.97, 3 .84, and 7.48 min, respectively, were obtained. Five milligrams of each glycerol ether was dissolved in 1 ml of 95% ethanol. This solution was then serially diluted with sterile water to a concentration of 0.625 mg/ml to reduce the ethanol concentration present in the assay. The highest ethanol concentration present in the assay was 0.78%. The ethanol solution was then serially diluted down in each successive well along with the drug combinations. A stock solution of AmB (45% AmB [by weight], 35% sodium deoxycholate, 20% sodium phosphate; Sigma) was prepared at a concentration of 2 mg/ml in sterile water, and the solution was kept at 20°C in the dark. A fresh working solution of 50 jig/ml was prepared daily from the stock solution for all assays. As a control, ethanol and sodium deoxycholate alone were tested in the assay with either DDG or AmB at the concentrations present in the DDG and AmB preparations and at higher concentrations.
A stock solution of fluconazole (intravenous preparation; Roerig, New York, N.Y.) of 2 mg/ml in sterile water was diluted to 10 ,.g/ml. This was the starting concentration of fluconazole in the checkerboard assay with DDG (13) .
Growth medium and assay conditions. A loopful of cells from the culture plate of each strain was transferred to a chemically defined synthetic liquid medium (9, 10) , and the cells were allowed to grow overnight at 25°C for C. albicans and at 37°C for all other yeasts on a gyratory shaker at 200 rpm. An aliquot of these cultures was then added to fresh liquid medium, and the cultures were allowed to grow under the conditions described above. Analysis of the growth of these cultures was done by measuring the A675 with a Spectronic 21 instrument (Bausch & Lomb, Inc. combination of the two drugs AmB and DDG on fungal growth (13 Assessment of drug interactions. To interpret drug interactions, the MICs of the individual drugs and the MICs of all drug combinations were plotted to form an isobologram. If the drug combinations were synergistic, the isobole is concave (move toward the axes). If the combination is additive, the isobole is planar. If the combination is antagonistic, the isobole is convex (move away from the axes) (13, 20) . The second method of assessing drug interactions was measurement of the fractional inhibitory concentration (FIC). This is the concentration of each drug in combination that produces inhibition of growth expressed as a fraction of the concentration that inhibits growth when the drug is used alone: FIC = (MIC of drug A in combination/MIC of drug A alone) + (MIC of drug B in combination/MIC of drug B alone). If the sum of the FIC is equal to 1, the interaction is additive; if the sum is less than 1, the interaction is synergistic; if the sum is greater than 1, the interaction is antagonistic (20) .
Electron microscopy. C neoformans cells were treated overnight with 2.5 ,Ig of DDG per ml at 37°C with continual shaking and aeration. The cells, both treated and untreated, were prepared by a previously described method (7) . Briefly, cells were fixed with formalin, dried in a critical-point apparatus (Polaron Instruments, Hatfield, Pa.), and replicated with platinum carbon in a model BA-360M high-vacuum unit (Balzers High Vacuum Co., Liechtenstein). RESULTS DDG was tested against species of Candida and Cryptococcus for its antifungal activity. DDG was found to inhibit the growth of both genera. DDG and AmB were tested by the standard checkerboard assay to determine whether they had favorable or unfavorable antifungal interactions. The first two yeasts assayed by this technique were C. albicans ( Fig. 2A) and C. neoformnans (Fig. 2B) at 37°C. Both the MICs and MFCs for each yeast were graphed in isobolograms and yielded highly concave curves, characteristic of strong drug synergism (20) . Similar results were obtained at 25°C (data not shown). Six different strains of C. neoformans were tested to show that this synergistic interaction was not specific to the particular clinical isolate first assayed. All strains were equally susceptible to the drug combinations (data not shown). This synergistic interaction was obtained with a variety of species from the two very different genera of yeasts, Cryptococcus and Candida. Figure 3 illustrates that three different species of Cryptococcus, C. albidus, C. laurentii, and C. neofornans, were readily killed by low concentrations of DDG and AmB. Figure 4 demonstrates that three species of Candida, C. tropicalis, C. parapsilosis, and C. albicans, also exhibited equal susceptibilities to these combinations of AmB and DDG. For comparison with the MICs of the drug combinations that were obtained, Table 1 depicts the MICs of DDG and AmB alone for all species tested. A second method of interpreting the drug interactions between DDG and AmB is the FIC. The more the FIC is less than 1, the greater the degree of synergism. All FICs obtained in all the tests (all species and strains from both genera) were calculated to be less than 1; the optimal FICs for all species tested were less than 0.4 (Table 2) . Sodium deoxycholate was used as a control to show that DDG did not elicit its fungicidal activity through a simple detergent-like action. The same checkerboard assay was used, except that sodium deoxycholate replaced DDG. This combination resulted in indifferent drug interactions. Sodium deoxycholate used at concentrations considerably greater than the effective concentrations of DDG had no fungicidal effect on its own and did not potentiate the inhibitory action of AmB on the yeasts studied (data not shown). Ethanol was also tested to determine whether it had any drug interactions with either DDG or AmB. It was used at the concentration present in the DDG preparation and at higher concentrations and did not have any synergistic interaction with either DDG or AmB. In the checkerboard assay, the yeasts were inhibited by either DDG at its MIC or AmB at its MIC, but they were not inhibited by ethanol until the ethanol concentration was fourfold greater than its greatest concentration in the DDG preparation (data not shown). The synergistic interaction with AmB was not limited to DDG, the glycerol ether with a 12-carbon alkyl side chain. Various degrees of synergism were obtained with combinations of AmB and a range of saturated glycerol ethers with carbon chain lengths ranging from 8 to 16 against C. neofornans ( Fig. SA  and B) . Also, an unsaturated C-18 glycerol ether (1-0-9'-cisoctadecenyl-sn-glycerol; selachyl alcohol) demonstrated that this synergism was not limited to saturated glycerol ethers (Fig.   SB) . Nor was any preference given to any of the three stereoisomers (sn-1, sn-2, and sn-3) of DDG (data not shown).
The same results were obtained with C. albicans (data not shown).
DDG was also tested in combination with fluconazole against C. neoformans for any favorable or unfavorable drug Electron micrographs were taken to determine if any structural changes took place in C. neoformans after treatment with DDG alone. C. neoformans has a polysaccharide capsule that covers the plasma membrane and cell wall and that is filamentous in appearance (Fig. 7A) . The capsule is a factor important for the virulence of the organism and protects it from phagocytic action (6) . When C. neoformans was treated overnight at room temperature with a sub-MIC of DDG (2.5 ,ug/ml), it grew (Fig. 7B ) and in some cases was so malformed that it dissociated from the cell wall (Fig. 7C) .
DISCUSSION
The results presented here indicate a strong synergistic interaction between DDG and AmB in inhibiting the growth of both Candida and Cryptococcus species. The synergistic concentrations of DDG and AmB that produced growth inhibition of both genera of yeasts were essentially the same, suggesting a common mechanism for the synergy between DDG and AmB. It is possible that DDG acts by a mechanism which alters the fluidity of the fungal membrane because it is less hydrophobic than the usual membrane glycerolipids. However, this is not a simple detergent effect. The natural detergent sodium deoxycholate (also present in commercial AmB preparations) had no effect at the concentrations of DDG that killed the fungi, nor did sodium deoxycholate have any synergistic effect when it was used in combination with AmB. The concentrations at which DDG functions are too low for it to be working as a surfactant, detergent, or emulsifier, which simply dissolves away the lipid-soluble compounds of the membrane resulting in the lysis or rupture of the membrane. Rather, we hypothesize that the fluidity of the membrane changes sufficiently to alter the hydrophobic environment, which changes the activity of key membrane-bound enzymes. There is prior evidence for this type of mechanism in that gram-positive bacteria are readily killed by DDG. DDG stimulates the degradative enzyme autolysin, which catalyzes the hydrolysis of the cell wall and when present in proper concentrations is essential for normal cell division (16, 18) . DDG also interferes with cell wall synthesis by inhibiting peptidoglycan synthesis (17) . When DDG acts synergistically with AmB, it is possible that some of the enzymes, whose activities have been altered because of the membrane fluidity changes elicited by DDG, are cell wallsynthesizing or cell wall-degrading enzymes. AmB kills fungi by binding to the ergosterol in the membrane. The major deterrent to AmB for reaching the ergosterol in the membrane is the tight framework of the cell wall (4, 12, 14) . This situation suggests a possible mechanism for the synergy observed between DDG and AmB. If DDG is acting to weaken the cell wall because of altered cell wall-synthesizing and/or -degrading enzyme activity, then AmB would have increased access to the membrane ergosterol. The electron micrograph studies with C. neoformans seem to support this hypothesis. The capsule of C. neoformans is predominantly composed of a polysaccharide which has a 1-3-mannose backbone and side chains of xylose and glucuronate (22) . Preliminary studies indicated that DDG inhibits the incorporation of [14C]glucose into the polysaccharide components of the cell walls of C. neoformans and C. albicans, and this inhibition seems to occur before the inhibition of protein synthesis (prior to cell death) (unpublished data). These data support the hypothesis of an altered membrane enzyme activity.
DDG seems to interact with lipid-soluble compounds such as AmB and penicillin G (19) and not with water-soluble compounds such as fluconazole. Fluconazole does not bind to lipid components in the membrane but acts by inhibiting a key enzyme in ergosterol synthesis (2) .
Ether-linked lipids occur naturally in a variety of animal tissues (15) . The fact that the synergistic interaction with AmB was not limited to DDG has important physiological and pharmacological implications. Fatty acids with chain lengths of 12 to 18 carbon atoms are relatively prevalent in animal tissues. The fact that alkyl glycerol ether lipids, such as batyl, chimyl, and selachyl alcohols, are natural products suggests that these fatty acids are processed to alkyl glycerol ethers via the alkyldihydroxyacetone-phosphate synthase pathway (15) . This further implies that alkyl glycerol ethers could function as antimicrobial agents within cells of animal tissues. That is, the alkyl glycerol ethers may be important natural factors in animals that protect against microbial infection. Their presence as natural protective factors would further suggest that these glycerol ethers should be readily tolerated by animal tissues when administered as drugs. Weber (21) demonstrated that mice could be fed DDG at 1 g/kg of body weight per day for 4 weeks without any adverse effects.
It is interesting that DDG acts synergistically with AmB to inhibit different species of Candida and Cryptococcus because patients treated with AmB often develop fungemia with other species of Candida. These species, such as C tropicalis and C. parapsilosis, result in infections that are more difficult to treat (8) . The results presented here are very encouraging for the development of new antifungal therapy in an area where there is an obvious dearth of effective antifungal drugs. Many more studies will have to be performed to begin to discern the mechanism of growth inhibition by DDG alone and the mechanism of synergy between DDG and AmB.
